# Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

> **NCT03623321** · PHASE3 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 595 (actual)

## Conditions studied

- Neuropsychiatric Symptoms Related to Neurodegenerative Disease

## Interventions

- **DRUG:** Pimavanserin

## Key facts

- **NCT ID:** NCT03623321
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-17
- **Primary completion:** 2023-05-05
- **Final completion:** 2023-05-05
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03623321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03623321, "Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03623321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*